USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME

Provided is a use of a mitoxantrone hydrochloride liposome in the preparation of a drug for treating urothelial cancer, breast cancer, and bone and soft tissue sarcoma. Further provided is a method for treating urothelial cancer, breast cancer, and bone and soft tissue sarcoma, and the method is to administer a therapeutically effective amount of mitoxantrone hydrochloride liposomes to a patient in need. The mitoxantrone hydrochloride liposome can effectively treat urothelial cancer, breast cancer, and bone and soft tissue sarcoma, and compared with common mitoxantrone hydrochloride injections, the mitoxantrone hydrochloride liposome has better therapeutic effect and fewer adverse reactions..

Medienart:

Patent

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Europäisches Patentamt - (2024) vom: 21. Feb. Zur Gesamtaufnahme - year:2024

Sprache:

Englisch

Beteiligte Personen:

LI CHUNLEI [VerfasserIn]
LIU YANPING [VerfasserIn]
LIANG MIN [VerfasserIn]
LI MENGMENG [VerfasserIn]
LI TONG [VerfasserIn]
YANG HUA [VerfasserIn]
WANG SHIXIA [VerfasserIn]
YANG SENSEN [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2024-02-21, Last update posted on www.tib.eu: 2024-03-05, Last updated: 2024-03-08

Patentnummer:

EP4324456

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA019270070